vs

Side-by-side financial comparison of OFF THE HOOK YS INC. (OTH) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $24.0M, roughly 1.2× OFF THE HOOK YS INC.). OFF THE HOOK YS INC. runs the higher net margin — -0.3% vs -71.0%, a 70.7% gap on every dollar of revenue. OFF THE HOOK YS INC. produced more free cash flow last quarter ($-867.2K vs $-31.8M).

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

OTH vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.2× larger
ZYME
$27.6M
$24.0M
OTH
Higher net margin
OTH
OTH
70.7% more per $
OTH
-0.3%
-71.0%
ZYME
More free cash flow
OTH
OTH
$31.0M more FCF
OTH
$-867.2K
$-31.8M
ZYME

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
OTH
OTH
ZYME
ZYME
Revenue
$24.0M
$27.6M
Net Profit
$-66.7K
$-19.6M
Gross Margin
12.6%
Operating Margin
1.3%
-80.1%
Net Margin
-0.3%
-71.0%
Revenue YoY
72.6%
Net Profit YoY
34.3%
EPS (diluted)
$-0.00
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OTH
OTH
ZYME
ZYME
Q3 25
$24.0M
$27.6M
Q2 25
$48.7M
Q1 25
$27.1M
Q4 24
$31.0M
Q3 24
$16.0M
Q2 24
$19.2M
Q1 24
$10.0M
Net Profit
OTH
OTH
ZYME
ZYME
Q3 25
$-66.7K
$-19.6M
Q2 25
$2.3M
Q1 25
$-22.6M
Q4 24
$-23.5M
Q3 24
$-29.9M
Q2 24
$-37.7M
Q1 24
$-31.7M
Gross Margin
OTH
OTH
ZYME
ZYME
Q3 25
12.6%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
OTH
OTH
ZYME
ZYME
Q3 25
1.3%
-80.1%
Q2 25
-1.4%
Q1 25
-94.5%
Q4 24
-71.6%
Q3 24
-213.8%
Q2 24
-222.9%
Q1 24
-376.9%
Net Margin
OTH
OTH
ZYME
ZYME
Q3 25
-0.3%
-71.0%
Q2 25
4.8%
Q1 25
-83.5%
Q4 24
-75.8%
Q3 24
-186.6%
Q2 24
-195.8%
Q1 24
-315.6%
EPS (diluted)
OTH
OTH
ZYME
ZYME
Q3 25
$-0.00
$-0.26
Q2 25
$0.03
Q1 25
$-0.30
Q4 24
$-0.32
Q3 24
$-0.39
Q2 24
$-0.49
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OTH
OTH
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$2.3M
$64.8M
Total DebtLower is stronger
$287.2K
Stockholders' EquityBook value
$-610.5K
$320.1M
Total Assets
$32.6M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OTH
OTH
ZYME
ZYME
Q3 25
$2.3M
$64.8M
Q2 25
$98.3M
Q1 25
$76.2M
Q4 24
$66.1M
Q3 24
$122.4M
Q2 24
$71.0M
Q1 24
$114.8M
Total Debt
OTH
OTH
ZYME
ZYME
Q3 25
$287.2K
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
OTH
OTH
ZYME
ZYME
Q3 25
$-610.5K
$320.1M
Q2 25
$334.5M
Q1 25
$325.0M
Q4 24
$338.8M
Q3 24
$367.0M
Q2 24
$406.2M
Q1 24
$438.0M
Total Assets
OTH
OTH
ZYME
ZYME
Q3 25
$32.6M
$397.3M
Q2 25
$408.4M
Q1 25
$425.5M
Q4 24
$463.1M
Q3 24
$487.2M
Q2 24
$515.6M
Q1 24
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OTH
OTH
ZYME
ZYME
Operating Cash FlowLast quarter
$-664.2K
$-31.4M
Free Cash FlowOCF − Capex
$-867.2K
$-31.8M
FCF MarginFCF / Revenue
-3.6%
-115.2%
Capex IntensityCapex / Revenue
0.8%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OTH
OTH
ZYME
ZYME
Q3 25
$-664.2K
$-31.4M
Q2 25
$12.1M
Q1 25
$-3.4M
Q4 24
$-41.5M
Q3 24
$-5.9M
Q2 24
$-25.0M
Q1 24
$-37.7M
Free Cash Flow
OTH
OTH
ZYME
ZYME
Q3 25
$-867.2K
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
OTH
OTH
ZYME
ZYME
Q3 25
-3.6%
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
OTH
OTH
ZYME
ZYME
Q3 25
0.8%
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
OTH
OTH
ZYME
ZYME
Q3 25
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons